Of note, no difference in survival was instead observed for the recipients of ETO-treated vs vehicle-treated miR-142+/+BCR-ABL LSKs (median survival: 214 vs 192 days, p = 0.7; Supplementary Fig. 8f), suggesting higher relevance of this metabolic process to the activity of BC-LSCs compared with that of CP-LSCs. Here, ABL1 is linked to breast cancer.